argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 39.05B |
| Revenue (ttm) | 2.66B |
| Net Income (ttm) | 1.09B |
| Shares Out | 61.20M |
| EPS (ttm) | 15.96 |
| PE Ratio | 39.97 |
| Forward PE | 36.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,776 |
| Average Volume | 84,301 |
| Open | 642.40 |
| Previous Close | 638.00 |
| Day's Range | 641.20 - 644.80 |
| 52-Week Range | 456.30 - 664.80 |
| Beta | 0.00 |
| RSI | 68.26 |
| Earnings Date | Oct 30, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
argenx: Bullish On This R&D Focused Biotech Stock
argenx's blockbuster Vyvgart drives rapid growth, but heavy reliance on one product and US sales creates concentration risk. The company's robust R&D investment and Immunology Innovation Program fuel ...
Deutsche Bank Downgrades Argenx (ARGX) Rating Amid Valuation Concerns
Deutsche Bank Downgrades Argenx (ARGX) Rating Amid Valuation Concerns
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 26.74%. Currently, argenx has a market capitalization of...
Is argenx Gaining or Losing Market Support?
argenx's (NYSE: ARGX) short percent of float has fallen 4.11% since its last report. The company recently reported that it has 1.81 million shares sold short , which is 3.27% of all regular shares th...
Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
B of A Securities Raises Price Target on ARGX to $887 | ARGX Stock News
B of A Securities Raises Price Target on ARGX to $887 | ARGX Stock News
argenx to Present at Upcoming Investor Conferences
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Argenx saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 94 the day before.
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
Argenx SE (NASDAQ: ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod...
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
Argenx SE ARGX stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab)...
Argenx Tops Buy Point On Bullish Study, 850 Price Target
Argenx announced positive study results and plans to seek FDA approval to expand its label for Vyvgart.
Argenx Targets FDA Label Expansion After Vyvgart Trial Success
Argenx reported positive Phase 3 Vyvgart data in ... Full story available on Benzinga.com
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegati...
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contac...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contac...
Monica Seles: Reveals Myasthenia Gravis Diagnosis; champion's battle against Autoimmune Disease
Tennis legend Monica Seles, a nine-time Grand Slam champion, reveals her three-year battle with myasthenia gravis (MG), a rare neuromuscular disease. At 51, Seles is speaking out to raise awareness, p...
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contac...
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 10.06% on an annualized basis producing an average annual return of 23.85%. Currently, argenx has a market capitalization of...
Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX). Such investors are advised to contact Dan...